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Abstract. Mass drug administration (MDA) with azithromycin (AZ) has been used successfully to control trachoma.
However, several studies have shown that MDA with AZ has led to the emergence of resistance to AZ in Streptococcus
pneumoniae. The emergence of resistance to AZ has also been observed when this antibiotic was combined with the
antimalarials used for seasonal malaria chemoprevention (SMC). The development of antibiotic resistance, including
resistance to AZ, is sometimes associatedwith the emergence of a bacterial clone that belongs to a specific serotype.We
hypothesize that the increase in resistance of S. pneumoniae observed after 3 years of SMCwith AZmight be associated
with a change in the distribution of pneumococcal serotypes. Therefore, 698 randomly selected isolates from among the
1,468 isolates ofS. pneumoniaeobtainedduring carriage studies undertaken during anSMCplusAZ trial were serotyped.
A polymerase chain reaction (PCR) multiplex assay using an algorithm adapted to the detection of the pneumococcal
serotypes most prevalent in African countries was used for initial serotyping, and the Quellung technique was used to
complement thePCRtechniquewhennecessary. Fifty-six serotypesweredetectedamong the698 isolatesofS.pneumoniae.
Aswift appearanceanddisappearanceofmanyserotypeswasobserved,butsomeserotypes including6A,19F,19A,23F,and
35B were persistent. The distribution of serotypes between isolates obtained from children who had received AZ or placebo
was similar. An increase in AZ resistance was seen in several serotypes following exposure to AZ. Mass drug administration
withAZ led to theemergenceof resistance inpneumococci of several different serotypes anddid not appear tobe linked to the
emergence of a single serotype.
INTRODUCTION
Many sub-Saharan African countries use azithromycin (AZ)
in mass drug administration (MDA) programs to control tra-
choma.1 Previousstudieshave shown that in communitieswith
a high childmortality, MDAwith thismacrolide can significantly
reduce mortality in children younger than 5 years.2–6 Several
studiesofMDAwithAZ for thecontrol of trachomahavenoteda
temporary increase in the resistance of Streptococcus pneu-
moniae to AZ.3,4,6–14 In a study conducted in Burkina Faso, in
which the impact of the addition of AZ to the antimalarials used
for seasonalmalaria chemoprevention (SMC) on childmortality
and morbidity was investigated, we found that the prevalence
of pneumococcal carriage decreased over time but that there
was an increase in the prevalence of S. pneumoniae to AZ
which persisted for a year after AZ administration has been
stopped. Resistance to AZ was more pronounced in the chil-
dren receiving AZ than in the controls.15
The emergence of antibiotic resistance, including resistance
to AZ, in S. pneumoniae is sometimes linked to the emergence
of a single serotype.16,17 Thus, we considered that we might
find changes in the serotype distribution of nasopharyngeal
isolates ofS. pneumoniaebefore and after administration of AZ
with SMC for 3 years. This article reports the findings of a study
designed to test this hypothesis.
MATERIALS AND METHODS
Study design.Samples for this study were collected during
the course of a large clinical trial which investigated the
potential benefit of adding AZ to SMC with sulfadoxine–
pyrimethamine plus amodiaquine (SP + AQ) on child mortality
and admissions to hospital which was conducted from 2014
to 2016 in children aged 3–59 months in Burkina Faso and
Mali. No impact was observed on the primary trial end point of
death or hospital admission, but a reduction in clinic atten-
dances with acute respiratory or gastrointestinal infections
and skin diseases accompanied by fever was observed.
During each malaria transmission season, children enrolled
in the trial received four courses of SMC per year 1 month
apart. Infants aged 3–11months received SP 250mg/12.5mg
and AQ 75 mg on day 1 and AQ 75 mg on days 2 and 3. In
addition, they received AZ 100mg ormatching AZ placebo on
days 1, 2, and 3. Children aged 1–4 years received double
these doses. Sulfadoxine–pyrimethamine + amodiaquine was
supplied by Guilin Pharmaceutical (Shanghai, China), and AZ
and matching placebo by CIPLA (Mumbai, India). All doses of
treatments were given by trial staff. Coverage with monthly
treatmentswashigh,withmore than 80%of children receiving
three or four rounds of treatment each year.6
In 2013, Burkina Faso began the introduction of pneumo-
coccal conjugate vaccination 13 (PCV13) into the Expanded
Programme of Immunization. Coverage with three doses of
PCV13 was 58.3% before the 2015 malaria transmission
season. An increase in the coverage rate was observed in
2016.
A sub-study to determine the impact of administration of AZ
in associationwithSMCon the resistanceofS. pneumoniae to
this antibiotic was nestedwithin themain SMC+AZ trial. Each
year, over a period of 3 years, 400 Burkinabe children were
randomly selected for inclusion in a nasopharyngeal carriage
study. Different children were selected each year. After writ-
ten, informed consent had been obtained from a parent or
guardian, a nasopharyngeal swab was collected before the
first round of SMC and 1 month after the last round of SMC
each year. The trial was approved by the National Ethics
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Committee in Burkina Faso (approval number 2016-11-126)
and by the Ethics Committees at the London School of Hy-
giene & Tropical Medicine. It was also registered on the
website, clinicaltrials.gov (NCT02211729).
Collection of nasopharyngeal samples. Nasopharyngeal
swabs were collected using a calcium alginate swab from the
posterior wall of the nasopharynx and immediately transferred to
vials containing skim milk–tryptone–glucose–glycerol medium.
Vials were stored in a cold box before transfer to the laboratory
within 8 hours of collection, and the vials were stored at−80C in
accordance with the WHO protocol for the evaluation of pneu-
mococcal carriage.
Laboratory testing. Details about the isolation and char-
acterizationofpneumococci havebeenpresentedpreviously.15
A single representative colony, selected on the basis of its ap-
pearance, was sampled per plate. Antibiotic sensitivity was
measured using antibiotic impregnated discs. Resistance to
penicillin and macrolides was confirmed by E-test strips.
Serotyping was performed by sequential multiplex PCR using
an algorithm designed for Africa.18 Eight series of PCRs in-
cluding four to five serotypes per series were performed for the
detection of 40 pneumococcal serotypes. DNA extracts were
obtained by suspending frozen isolates in 500 μL PBS buffer
and heating them to 100C for 10 minutes (see Supplemental).
All pneumococcal isolates determined to be non-typeable by
PCR or for which the serotype was unclear were further tested
by the Quellung reaction with antisera prepared in the Strep-
tococcus Laboratory at the CDC, Atlanta.
Data management and statistical analysis. For logistic
reasons, it was not possible to serotype all the pneumococcal
isolates obtained during the 3 years of the study. A random
selection of approximately half the isolates (698/1,418) (49.2%)
was selected for serotyping.
Baseline sociodemographic and clinical data were collected
on hard copy case report forms, and laboratory results were
recorded in the first instance in laboratory books before being
transferred into an electronic database using Excel. Data were
cleaned and analyzed with Stata version 15.0 software (Stata
Corp LLC, College station, TX). Data were presented as pro-
portions and compared using chi2 or Fisher’s exact test. A
Poisson regression model was used to estimate the prevalence
ratios between treatment arms at each survey. Vaccine sero-
types (0 or 1) and resistance to azithromycin (0 or 1) were the
dependent variables, whereas the treatment arm (0 or 1) and the
survey (1–6) were the independent ones. The significance
threshold used for statistical tests was P < 0.05.
RESULTS
During the course of six carriage surveys undertaken be-
tween 2014 and 2016, 2,565 nasopharyngeal samples were
taken from children aged 3–59 months, from which 1,418
isolates of S. pneumoniaewere obtained. Six hundred ninety-
eight of these isolates, equitably distributed among the sur-
veys, were randomly selected for serotyping (Figure 1). The
PCR and/or Quellung test detected 56 different serotypes.
Baseline survey. Streptococcus pneumoniae was isolated
from 230 (67%) of the 430 nasopharyngeal samples collected
at the first pre-intervention survey (baseline), and 134 (58.3%)
of these isolates were serotyped. Thirty-two unique serotypes
were identified and classified into vaccine-type (VT) and
non–vaccine-type (NVT) serotypes, as shown in Figure 2.
Vaccine serotypes accounted for 49.3% of the isolated sero-
types; 37.7% of children who carried a pneumococcus of VT
had received at least one dose of PCV13.
The most frequently encountered serotypes were 6A, 19F,
23F, and 6B, which represented 42.2% of the serotyped iso-
lates. A high prevalence of serotype 6A (17.8%) was isolated
among the strains serotyped.
Subsequent pretreatment surveys. Nasopharyngeal car-
riage surveys were carried out before the administration of AZ
or placebo in years 2 and 3 of the study. There were substantial
differences between the serotype distribution found in the
second and third pretreatment surveys compared with the
FIGURE 1. Flowchart for the study of the effect of azithromycin administration on nasopharyngeal serotype of Streptococcus pneumoniae,
Burkina Faso, 2014–2016. Numbers in the lowest row of the boxes show the numbers of isolates that were serotyped at each survey.
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baseline (Figures 2–4),witha significant decrease frombaseline
in the percentage of VT 49.3–35.4%, P = 0.020% and 49.3%
versus 22.6%, P < 0.001 for years 2015 and 2016, respectively
(Figure5). A change in serotypedistributionwasnotedbetween
the baseline survey and subsequent pre-intervention surveys
with some new serotypes appearing, whereas some of those
found initially were absent. No significant differences were
found in thedistributionof serotypesbetweenchildren in theAZ
andplacebogroup (Figure5,Supplemental TableS4). Themost
frequently identified serotypeswere 23F, 13, 19F, 35B, and10A
in the 2015 pretreatment survey and 35B, 13, 21, and 34 in the
2016 pretreatment survey.
Posttreatment surveys. A diversity of serotypes was seen
also in the posttreatment surveys. Thepredominant serotypes
remained very similar to those seen before administration of
AZ with 6A, 19F, and 23F predominating (Figures 2–4); 35B
was the most predominant serotype among the NVT isolates,
with aprevalence ranging from3.9%to10.0%.Theproportion
of vaccine serotypes decreased between the baseline (pre-
treatment) and the last posttreatment survey (49.3% versus
27.5% P = 0.002). This decrease was similar in the two-
treatment arm (Figure 5, Supplemental Table S4).
Serotypes and AZ resistance. Only three of the 134 chil-
dren fromwhomapneumococcuswas isolated in the first pre-
intervention baseline survey carried an AZ-resistant strain of
S. pneumoniae (serotypes 6B, 15A, and 35B). In 2014, the
prevalenceofAZ-resistant strains ofS.pneumoniae increased
from 2.2% (3/134) in the pretreatment survey to 12.5% (18/
144) in the posttreatment survey (P = 0.001). This increase
involved serotypes 4, 6A, 7F, 14, 15C, 19A, 19F, 21, 23F, 24A,
and 35B. In 2015, there was no significant difference between
the prevalence of AZ-resistant strains in the pretreatment
survey (10.4% [15/144]) versus the posttreatment surveys
(16.5% [17/103]), P = 0.160.). The serotypes with the highest
azithromycin resistance posttreatment were 6A, 19A, 23F, 21,
and 35B. However, in 2016, an increase in the prevalence of
AZ-resistant strains from 7.5% (7/93) in the pretreatment to
26.6% (21/79) in the posttreatment surveyswasobserved (P=
0.001) (Supplemental Table S4 and Figure S1). Resistant
strains included serotypes 6A, 23F, 13, 10A, 15C, 23B, and
35B.Overall, four serotypes35B (2%), 23F (0.9%), 19F (0.9%),
and 6A (0.7%) had the most AZ-resistant isolates.
FIGURE 3. Distribution of nasopharyngeal pneumococcal sero-
types before and after azithromycin administration in 2015. The pro-
portions of serotypes detected at the respective study visit are shown:
orange bars represent azithromycin-susceptible isolates, and blue
bars represent azithromycin-resistant isolates. Pneumococcal con-
jugate vaccination 13 vaccine-type (VT) serotypes are grouped at the
bottom of the figure. This figure appears in color at www.ajtmh.org.
FIGURE 2. Distribution of nasopharyngeal pneumococcal serotypes be-
fore and after azithromycin administration in 2014. The proportions of se-
rotypes detected at the respective study visit are shown: orange bars
represent azithromycin-susceptible isolates, and blue bars represent azi-
thromycin-resistant isolates. Pneumococcal conjugate vaccination 13 vac-
cine-type (VT) serotypes are grouped at the bottomof the figure. This figure
appears in color at www.ajtmh.org.
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DISCUSSION
This study investigated the impact of MDA with AZ given
monthly for 4 months each year for 3 years on the distribution
of pneumococcal serotypes. During the period of the study, a
diversity of serotypes was observed. There was a swift ap-
pearance and disappearance of many serotypes between
years, but serotypes 6A, 19A, 19F, 23F, and 35B persisted.
Similar studies conducted in other African countries observed
the same patterns.4,19 These prevalent serotypes were found
in both pre- and posttreatment and also in children who re-
ceived or did not receive AZ.
We previously reported that the prevalence of pneumo-
coccal carriage decreased overall during the three years of the
study, whereas the prevalence of isolates resistant to AZ in-
creased in both children who received AZ and in children in
neighboring households who received placebo, but re-
sistance was more marked in the former.15 This increase in
resistance of S. pneumoniae to AZ, associated with cross-
resistance to erythromycin, could have clinical consequences
as the latter antibiotic is sometimes used for the treatment of
pneumonia and generation of AZ resistance in other bacteria
not investigated in this study, for example, gut bacteria, but
could also be clinically important.
We considered that the increase in resistance to AZ ob-
served during the course of the study might be due to the
emergence of resistance in a single serotype. However, this
was not the case as resistance was seen in several serotypes.
Therewas no significant difference in the serotype distribution
of children who had received AZ or placebo.
Although administration of AZ did not change the distribu-
tion of serotypes, a reduction in carriagewith VTwas noted as the
study progressed. The prevalence of carriage of VT pneumococci
decreased from 49.3% in the first baseline survey to 27.5% in the
final one. The reduction in VT was seen in both the azithromycin
and placebo group (Figure 5) and may have been linked to the
introduction of PCV13 into the routine national vaccination pro-
gram in the year before the study started, with an increasing pro-
portion of children being vaccinated as the study progressed. Not
all children had a vaccination card, but based on the information
that was available, it is estimated that the proportion of children
who had received PCV13 increased from about 64% to 87%
during the course of the study.15 Carriage of pneumococci de-
clines with age, but the mean age of children in each survey was
similar. Carriage with serotypes 1 and 5 was found only in-
frequently, in four and one child, respectively, as reported inmany
previous carriage studies carried out in Africa.4,20–22 However,
pneumococci belonging to these serotypes are important causes
of invasive pneumococcal disease in sub-Saharan Africa.
One of the limitations of our study was that because of
budgetary constraints, we were only able to serotype ap-
proximately 50% of the isolated pneumococcal. However,
random sampling should have ensured that the serotype
distribution found in different surveys reflected the true situ-
ation. In addition, there were limitations in the information on
the vaccination status of all children in the study as parents
and/or legal guardians were not always able to provide full
documentations regarding their child’s vaccination record. An
FIGURE 4. Distribution of nasopharyngeal pneumococcal sero-
types before and after azithromycin administration in 2016. The pro-
portions of serotypes detected at the respective study visit are shown:
orange bars represent azithromycin-susceptible isolates, and blue
bars represent azithromycin-resistant isolates. Pneumococcal con-
jugate vaccination 13 vaccine-type (VT) serotypes are grouped at the
bottom of the figure. This figure appears in color at www.ajtmh.org.
FIGURE 5. Prevalence of pneumococcal isolates that were of vac-
cine serotype by treatment arm during the course of the trial.
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additional weakness of the study was that it was not possible
todowhole genomesequencing for financial reasons, and this
would have been able to identify if there had been an expan-
sion of a specific clone.
In conclusion, this study has shown that the increase in the
resistanceof nasopharyngeal isolatesofS.pneumoniaenoted
following MDA with AZ used in association with SMC was
probably not associated with the emergence of a single re-
sistant clone but due to the emergence of resistance in
pneumococci belonging to several different serotypes.
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